Research programme: T-cell receptor immunotherapies - bluebird bio/Medigene

Drug Profile

Research programme: T-cell receptor immunotherapies - bluebird bio/Medigene

Alternative Names: TCR immunotherapies - bluebird bio/Medigene

Latest Information Update: 06 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MediGene AG
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 06 Jun 2018 Medigene expands its research and development collaboration with bluebird bio for the development of T-cell receptor (TCR) immunotherapies
  • 06 Mar 2018 Medigene AG has patent protection for allo-restricted T cell identification method in Europe
  • 29 Sep 2016 Medigene and bluebird bio collaborate on the research and development of T-cell receptor immunotherapies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top